The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...
Analyst Etzer Darout of BMO Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), boosting the price target to $134.00.
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback